Ratings Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Market Closed - Nasdaq 16:00:00 2024-05-22 EDT 5-day change 1st Jan Change
31.71 USD 0.00% Intraday chart for Protagonist Therapeutics, Inc. +7.09% +38.29%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
+38.29% 1.86B
C
+64.23% 55.07B
B-
-2.31% 41.79B
B
+44.36% 40.22B
A
-8.29% 28.17B
C
+11.97% 26.28B
B-
-21.16% 18.93B
B
+7.54% 13.03B
B+
+27.17% 12.26B
C+
+25.72% 12.21B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PTGX Stock
  4. Ratings Protagonist Therapeutics, Inc.